ES2081618T3 - Metodo para diagnosticar anomalias de la coagulacion de la sangre. - Google Patents

Metodo para diagnosticar anomalias de la coagulacion de la sangre.

Info

Publication number
ES2081618T3
ES2081618T3 ES92913443T ES92913443T ES2081618T3 ES 2081618 T3 ES2081618 T3 ES 2081618T3 ES 92913443 T ES92913443 T ES 92913443T ES 92913443 T ES92913443 T ES 92913443T ES 2081618 T3 ES2081618 T3 ES 2081618T3
Authority
ES
Spain
Prior art keywords
conversion
sample
rate
blood coagulation
diagnosing blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92913443T
Other languages
English (en)
Other versions
ES2081618T5 (es
Inventor
Bjorn Dahlback
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26661244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2081618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9103332A external-priority patent/SE470274B/sv
Application filed by Individual filed Critical Individual
Publication of ES2081618T3 publication Critical patent/ES2081618T3/es
Application granted granted Critical
Publication of ES2081618T5 publication Critical patent/ES2081618T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UN METODO IN VITRO QUE ES PARTICULARMENTE UTIL PARA EL DIAGNOSTICO DE ENFERMEDADES TROMBOEMBOLICAS, TAL COMO LA TROMBOFILIA HEREDITARIA O NO HEREDITARIA, Y PARA DETERMINAR EL RIESGO POR TROMBOSIS A PROPOSITO DE EMBARAZO, TOMA DE PILDORAS ANTICONCEPTIVAS, CIRUGIA, ETC. EL METODO SE CARACTERIZA EN QUE EL SISTEMA DE COAGULACION EN UNA MUESTRA SE ACTIVA TOTAL O PARCIALMENTE DE UN MODO CONOCIDO DE POR SI E INCUBADO CON PROTEINA C ACTIVADA, DESPUES DE LO CUAL SE DETERMINA EL PROCENTAJE DE REACCION DE CONVERSION DE SUSTRATO COMO COAGULACION O CONVERSION DE UN SUSTRATO CROMOGENICO. EL PORCENTAJE DE CONVERSION OBTENIDO SE COMPARA CON LOS VALORES OBTENIDOS PARA MUESTRAS DE PLASMA NORMAL. SI EL PORCENTAJE SE AUMENTA, ESO INDICA QUE EL INDIVIDUO DEL CUAL SE DERIVA LA MUESTRA PUEDE SUFRIR UNA ENFERMEDAD TROMBOEMBOLICA.
ES92913443T 1991-11-13 1992-05-13 Metodo para diagnosticar anomalias de la coagulacion de la sangre. Expired - Lifetime ES2081618T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9103332 1991-11-13
SE9103332A SE470274B (sv) 1991-11-13 1991-11-13 Användning av en in vitro-metod för diagnos av blodkoagulationssjukdomar
US81130391A 1991-12-20 1991-12-20
US811303 1991-12-20

Publications (2)

Publication Number Publication Date
ES2081618T3 true ES2081618T3 (es) 1996-03-16
ES2081618T5 ES2081618T5 (es) 2005-09-01

Family

ID=26661244

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92913443T Expired - Lifetime ES2081618T5 (es) 1991-11-13 1992-05-13 Metodo para diagnosticar anomalias de la coagulacion de la sangre.

Country Status (10)

Country Link
EP (1) EP0608235B2 (es)
JP (1) JP2562000B2 (es)
AT (1) ATE132909T1 (es)
CA (1) CA2119761C (es)
DE (2) DE69207607T3 (es)
DK (1) DK0608235T4 (es)
ES (1) ES2081618T5 (es)
GR (1) GR3018646T3 (es)
HK (1) HK31697A (es)
WO (1) WO1993010261A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229933A1 (de) * 1992-09-08 1994-03-10 Max Planck Gesellschaft Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern
JPH08506181A (ja) * 1993-01-29 1996-07-02 ダールベック，ビョルン 新規抗凝固性補助因子活性
US5472852A (en) * 1993-09-15 1995-12-05 Oklahoma Medical Research Foundation Assay for detection of selective Protein C inhibition by patients
EP0656424B1 (de) * 1993-12-03 2002-02-06 Baxter Aktiengesellschaft Test zur Bestimmung der Empfindlichkeit gegenüber aktiviertem Protein C
CA2159907C (en) * 1994-02-14 2006-12-12 Rogier Maria Bertina A method for screening for the presence of a genetic defect associated with thrombosis and/or poor anticoagulant response to activated protein c
DE4418635C2 (de) * 1994-05-27 1997-07-24 Immuno Ag Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
AUPM731394A0 (en) * 1994-08-05 1994-09-01 Life Therapeutics Limited Improved activated protein c resistance test
EP0711838B2 (de) † 1994-11-10 2007-06-20 Dade Behring Marburg GmbH Verfahren zum spezifischen Nachweis eines aktivierten Gerinnungsfaktors V mit einer erhöhten Stabilität gegenüber aktiviertem Protein C
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders
US6867045B1 (en) 1994-11-14 2005-03-15 The Scripps Research Institute Method for diagnosis of thrombotic disorders
EP0718628B2 (en) † 1994-12-23 2005-02-23 Diagnostic Reagents Limited Method for diagnosis of blood coagulation disorders
US5874256A (en) * 1995-06-06 1999-02-23 Rijks Universiteit Leiden Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same
US5780255A (en) * 1995-06-09 1998-07-14 Instrumentation Laboratory, S.P.A. Protein C pathway screening test
AT403289B (de) * 1996-01-30 1997-12-29 Immuno Ag Verfahren zur herstellung eines standardisierten plasmapools für diagnostische zwecke
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
FR2764389B1 (fr) * 1997-06-06 1999-08-06 Stago Diagnostica Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee
DE19724239A1 (de) * 1997-06-09 1998-12-10 Max Planck Gesellschaft Dysprothrombinämie
US6743596B1 (en) 2000-10-27 2004-06-01 Biomerieux, Inc. Method of determining global coagulability hemostatic potential
US6855509B2 (en) 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US10662234B2 (en) 2011-06-07 2020-05-26 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
RU2518247C2 (ru) * 2011-07-26 2014-06-10 Общество с ограниченной ответственностью "ГемаКор Лабс" (ООО "ГемаКор Лабс") Способ определения пространственно-временного распределения активности протеолитического фермента в гетерогенной системе, устройство для реализации указанного способа и способ диагностики нарушений системы гемостаза по изменению пространственно-временного распределения активности протеолитического фермента в гетерогенной системе
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
RU2752776C1 (ru) * 2020-12-16 2021-08-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ определения длительности тромбопрофилактики низкомолекулярным гепарином после абдоминального родоразрешения у носителей мутации Лейден, генотип F5 G1691A

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001383A1 (en) * 1989-07-14 1991-02-07 Michigan State University Method for diagnosing blood clotting disorders
US5051357A (en) * 1989-07-14 1991-09-24 Board Of Trustees Operating Michigan State University Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5169786A (en) * 1989-12-19 1992-12-08 Ortho Diagnostic Systems, Inc. Method of determining levels of extrinsic and intrinsic clotting factors and protein c
EP0711838B2 (de) † 1994-11-10 2007-06-20 Dade Behring Marburg GmbH Verfahren zum spezifischen Nachweis eines aktivierten Gerinnungsfaktors V mit einer erhöhten Stabilität gegenüber aktiviertem Protein C
US5705395A (en) † 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders

Also Published As

Publication number Publication date
EP0608235A1 (en) 1994-08-03
JPH07501217A (ja) 1995-02-09
CA2119761C (en) 1997-12-16
EP0608235B1 (en) 1996-01-10
AU666484B2 (en) 1996-02-15
EP0608235B2 (en) 2005-05-04
DE69207607T2 (de) 1996-06-20
ATE132909T1 (de) 1996-01-15
DE69207607T3 (de) 2006-07-06
AU2198092A (en) 1993-06-15
GR3018646T3 (en) 1996-04-30
DK0608235T4 (da) 2005-05-30
DE69207607D1 (de) 1996-02-22
JP2562000B2 (ja) 1996-12-11
HK31697A (en) 1997-03-21
WO1993010261A1 (en) 1993-05-27
ES2081618T5 (es) 2005-09-01
DK0608235T3 (da) 1996-02-12
DE608235T1 (de) 1994-12-22
CA2119761A1 (en) 1993-05-27

Similar Documents

Publication Publication Date Title
ES2081618T3 (es) Metodo para diagnosticar anomalias de la coagulacion de la sangre.
CA2282746A1 (en) Prediction of coronary artery disease
DE69814639D1 (de) Nicht-invasive pränatale diagnose
ATE63168T1 (de) Kontroll- bzw. eichserum fuer die lipiddiagnostik.
DK0791175T3 (da) Separationsmidler udnyttende vakuum, til legemsvæsker
DK0868519T3 (da) Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
ES2151880T3 (es) Antagonistas de proteina de coagulacion de la sangre y sus utilizaciones.
KR930022086A (ko) 아밀로이드 전구체 단백질의 단백질가수분해에 근거한 알츠하이머병(Alzheimer's disease)의 진단분석
CA2346055A1 (en) Method and device for predicting physiological values
ES2058908T3 (es) Procedimiento para la separacion y purificacion de sialil-transferasas.
ES516496A0 (es) "procedimiento para la determinacion de hemoglobina glucosilada".
DE3783966D1 (de) Reagens zur pruefung von periodentalen erkrankungen.
FR2737732B1 (fr) Test co-dominant de diagnostic genetique
WO2004016065A3 (es) SISTEMA Y PROCEDIMIENTO INMUNOCROMATOGRÁFICO PARA LA INDENTIFICACIÓN SIMULTÁNEA DE ANTICUERPOS FRENTE A AGA Y t-TG, Y SU USO EN EL DIAGNOSTICO DE ENFERMEDAD CELIACA
CA2328955A1 (en) Fetal testing for prediction of low birth weight
WO2001065262A3 (en) Reagents and methods useful for detecting diseases of the breast
CA2332310A1 (en) Antibody against protein tyrosine phosphatase intracellular domains
ES2099876T3 (es) Procedimiento para la determinacion de anticuerpos de lupus anticoagulante que provocan trombosis.
RU2141667C1 (ru) Способ диагностики эрозивного гастродуоденита и язвенной болезни у детей
SU1435992A1 (ru) Способ гистологической диагностики синдрома дессеминированного внутрисосудистого свертывани крови
WO2001086292A3 (en) Ipg assay
AU5736899A (en) A mutant of tissue factor pathway inhibitor, dna sequence and use for detecting thrombotic disorders
KR880701886A (ko) 췌장효소원의 유리활성화 펩티드의 면역검정에 의한 질병의 진단, 위중도 예견, 및 모니터링
WO1999064584A3 (de) Protein zur regulation von apoptose
WO2002044723A3 (en) Method for diagnosing a predisposition of psychosis in a progeny

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 608235

Country of ref document: ES